Nanoparticle-mediated measurement of target-drug binding in cancer cells Academic Article uri icon


MeSH Major

  • Biosensing Techniques
  • Enzyme Inhibitors
  • Molecular Targeted Therapy
  • Nanoparticles
  • Nanotechnology
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerases


  • Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells, and drug delivery. The ability to rapidly quantitate drug response in cells harvested from patients in a point-of-care setting would have far reaching implications. Capitalizing on recent developments with miniaturized NMR technologies, we have developed a magnetic nanoparticle-based approach to directly measure both target expression and drug binding in scant human cells. The method involves covalent conjugation of the small-molecule drug to a magnetic nanoparticle that is then used as a read-out for target expression and drug-binding affinity. Using poly(ADP-ribose) polymerase (PARP) inhibition as a model system, we developed an approach to distinguish differential expression of PARP in scant cells with excellent correlation to gold standards, the ability to mimic drug pharmacodynamics ex vivo through competitive target-drug binding, and the potential to perform such measurements in clinical samples.

publication date

  • November 22, 2011



  • Academic Article



  • eng

PubMed Central ID

  • PMC3297118

Digital Object Identifier (DOI)

  • 10.1021/nn203450p

PubMed ID

  • 21962084

Additional Document Info

start page

  • 9216

end page

  • 24


  • 5


  • 11